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Blockade of the cardiac ion channel coded by human ether-à-gogo-related gene (hERG)
can lead to cardiac arrhythmia, which has become a major concern in drug discovery and
development. Automated electrophysiological patch clamp allows assessment of hERG
channel effects early in drug development to aid medicinal chemistry programs and has
become routine in pharmaceutical companies. However, a number of potential sources
of errors in setting up hERG channel assays by automated patch clamp can lead to
misinterpretation of data or false effects being reported.This article describes protocols for
automated electrophysiology screening of compound effects on the hERG channel current.
Protocol details and the translation of criteria known from manual patch clamp experiments
to automated patch clamp experiments to achieve good quality data are emphasized.Typical
pitfalls and artifacts that may lead to misinterpretation of data are discussed. While this
article focuses on hERG channel recordings using the QPatch (Sophion A/S, Copenhagen,
Denmark) technology, many of the assay and protocol details given in this article can be
transferred for setting up different ion channel assays by automated patch clamp and are
similar on other planar patch clamp platforms.
Keywords: hERG, Torsades de Pointes, cardiac arrhythmia, electrophysiology, automated patch clamp, safety
pharmacology, ion channel, ADMET
INTRODUCTION
A number of drug discovery and development programs
have been hampered by issues with drug induced cardiac
arrhythmia. This is particularly well-known for histamine
receptor antagonists, e.g., the potent human ether-à-gogo-
related gene (hERG) channel blocker Terfenadine (Teldane®,
Seldane®). Terfenadine is an H1 receptor antagonist that was
launched in 1982 and was later withdrawn from the mar-
ket because it potentially caused a life-threatening ventricu-
lar tachyarrhythmia, torsades de pointes. The potential to
affect cardiac ion channel currents and thereby potentially
induce cardiac arrhythmia can occur for compounds from
many different chemical classes and in very different therapeutic
areas.
hERG CHANNEL BLOCKADE CAN CAUSE CARDIAC ARRHYTHMIA
Nearly 20 years ago it was found that mutations in the hERG
could cause long QT syndrome. This inherited disorder can be
observed in the electrocardiogram as prolonged QT interval and
is correlated to torsades de pointes ventricular tachyarrhythmia
(Curran et al., 1995; Sanguinetti et al., 1995; Sanguinetti and
Tristani-Firouzi, 2006). The protein coded by hERG was later
identiﬁed as a potassium-selective cardiac ion channel, Kv11.1,
which plays an important role during cardiac repolarization. Con-
sequently, malfunction of this ion channel may cause a delay
in cardiac repolarization. The importance of the hERG ion
channel for drug discovery programs stems from the observa-
tion that not only mutations, but also drug induced blockade
of the channel, may cause repolarization abnormalities. Many
drugs from different chemical classes and therapeutic areas have
been shown to block the hERG-coded ion channel and may
in turn potentially trigger torsades (Bruin et al., 2005). Other
reasons for cardiac arrhythmias have been identiﬁed (Gintant
and Hoffman, 1984; Roden et al., 1996; Fenichel et al., 2004;
Gintant et al., 2011), but hERG channel blockade has become the
most frequent single cause for drug withdrawals (Fenichel et al.,
2004), and many drug discovery programs have been delayed
(imposing signiﬁcant costs on the pharmaceutical company)
or stopped due to hERG channel liabilities of potential drug
candidates.
Examples of compounds that show undesired hERG chan-
nel activity include Terfenadine, Astemizole (Zhou et al., 1999),
brompheniramine (Park et al., 2008) and many other drugs as
listed on, e.g., http://crediblemeds.org/everyone/composite-list-
all-qtdrugs/, a website maintained by the independent non-
proﬁt organization AZCERT, Arizona, and currently sponsored
by the Science Foundation Arizona. Reduction of hERG channel
liabilities is continuously and extensively discussed in the liter-
ature (Ito, 2009; Anderson et al., 2010; Davenport et al., 2010;
Levoin et al., 2011; Tye et al., 2011; Bahl et al., 2012; Becknell
et al., 2012; Hudkins et al., 2012; Moorthy et al., 2014). While
compounds from very different chemical classes may interact
with the hERG channel due to its relatively large hydropho-
bic pore, the property of hERG channel liability has been
observed especially often for histamine receptor antagonists.
The reason for this is that the pharmacophores of the hERG
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channel and the histamine receptor show remarkable similarities
(Davenport et al., 2010).
AUTOMATED PATCH CLAMP ELECTROPHYSIOLOGY IS AN EMERGING
TECHNIQUE FOR IDENTIFYING CARDIAC ION CHANNEL LIABILITIES
To identify potential hERG liabilities early in drug discovery pro-
grams and thus avoid problems with hERG channel interactions
for late-stage compounds, it has become common practice in drug
discovery programs to start testing compounds relatively early
during the drug discovery process on potential hERG channel
blockade. Finally, before administration to humans, the ICH S7B
guideline requests compounds to be tested on potential repolar-
ization issues under GLP, typically employing electrophysiological
patch clamp assays which are considered the “gold-standard” for
ion channel investigations.
A number of assays have been developed to gain a picture of
compound effects on the cardiac action potential and in particular
on repolarization effects. These assays include hERG ion channel
assays employing (but not being limited to) ﬂuorescence, binding,
atomic absorption or electrophysiological techniques measuring
interaction with, or the function of, the hERG ion channel, with
the different throughput inherent to these techniques. In addition,
assays have been developed that assess the effects of compounds
on other cardiac ion channels. These data may add important
information and draw a more complete picture on cardiac effects
than possible with hERG channel data alone, since effects on
other cardiac ion channelsmay potentiate or reduce hERGchannel
effects.
Also, assays that could potentially deliver more physiologically
relevant data than assays relying on only one ion channel type
are used. In the past years, techniques based on stem cell derived
cardiomyocytes particularly gained signiﬁcant interest (Hamdam
et al., 2013). Such assays integrate effects on several ion channels
beyond the hERG channel. Therefore effects on several channels
and interactions of such effects might be detected in assays using
these preparations.
Despite these efforts in developing, validating, and employ-
ing more complex assays (which might be considered especially
important for valuable late-stage compounds), the hERG ion
channel remains a major potential trouble maker in drug dis-
covery programs. It is therefore not surprising that interest in
this ion channel was one of the major drivers in developing auto-
mated electrophysiology patch clamp instrumentation (Dunlop
et al., 2008). Automated patch clamp assays have been success-
fully used in a number of drug discovery programs, both for
identifying compound effects on ion channel targets as well as
for identifying undesired off-target effects. Technical advances in
the automated patch clamp technique and in cell preparations
have facilitated employing automated patch clamp assays with
increasing success rates (Finkel et al., 2006; Zeng et al., 2008), high
parallelization (and, consequently, increased throughput), at (or
near) physiological temperature (Polonchuk, 2012), at increased
ligand application rates, and also using more challenging cell
preparations such as primary cells on these instruments (Farre
et al., 2009; Jones et al., 2009; Milligan et al., 2009; Golden et al.,
2011; Stoelzle et al., 2011a,b; Haythornthwaite et al., 2012; Becker
et al., 2013; Gillie et al., 2013; Milligan and Möller, 2013). The
development of higher throughput automated patch clamp instru-
ments has allowed moving electrophysiological ion channel assays
earlier into the drug discovery process and has made electro-
physiology measurements compatible with medicinal chemistry
iteration cycles. This is especially important for those drug dis-
covery programs in which hERG channel interactions could be
expected from earlier experiences with certain target (such as
histamine receptor programs, as noted above) or compound
classes.
In this manuscript we discuss protocols particularly suited for
measuring hERG ion channel effects during the Hit-to-Lead and
Lead Optimization phases in drug discovery programs. While
during high-throughput screening a small percentage of false
negatives or false positives could potentially be tolerated, this is
generally less acceptable during later stages of compound develop-
ment, as false or misinterpreted data might guide medicinal chem-
istry programs in the wrong direction. Therefore, for this article,
we focus on using medium throughput automated patch clamp
instrumentation, such as the QPatchTM (Sophion Biosciences A/S,
Copenhagen) or the Patchliner (Nanion Technologies GmbH,
Munich, Germany) automated electrophysiology platforms, to
deliver high data quality. These instruments allow 2 to 8 (Patch-
liner) or 8 to 48 (QPatch) parallel high quality measurements of
individual cells in the gigaseal conﬁguration. Importantly, many
of the notes and caveats discussed in this manuscript stem from
general (and partially basic) electrophysiological considerations.
Therefore, this basic electrophysiology, as well as cell prepara-
tion details, applies to most of the other automated patch clamp
platforms [e.g., SyncroPatch 96 and SyncroPatch 384 PE (Nanion
Technologies GmbH, Munich); PatchXpress, IonWorks Quattro,
Barracuda and Barracuda Plus (MDS, Sunnyvale, CA, USA); Ion-
Flux HT (Fluxion Bioscience Inc, San Francisco, CA, USA), Qube
(Sophion Biosciences A/S, Copenhagen)], and required validation
steps are very similar between the different instruments. Other
protocol details for measuring more challenging cell types, in
particular for cardiac safety evaluations using stem cell derived
cardiomyocytes using the Patchliner, may be found in other arti-
cles (Stoelzle et al., 2011a; Milligan and Möller, 2013). Protocol
optimization for other ion channels can be guided along some of
the notes discussed in this article.
MATERIALS
CELL LINE
A commercially available cell line (“CHO hERG DUO,” BSys,
Switzerland) was used (note 1).
CELL CULTURE AND CELL HARVESTING REAGENTS
Cell culture medium
450 ml HAM’s F-12 + Glutamax (Invitrogen, 31765)
+50 ml FBS Gold (PAA, A15-151)
+1 ml G418 = 100 μg/ml (PAA, P11-012)
+1 ml Hygromycin 100 μg/ml (PAA, P02-015)
Serum free medium
25 ml CHO-S-SFM I (Invitrogen, 12052)
+25 mM HEPES
+0.04 mg/ml Soy bean trypsin inhibtor (Sigma, T65222)
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+100 unit/ml Penicillin/Streptomycin [(P/S) Invitrogen15140]
Thawing medium
450 ml HAM’s F-12 + Glutamax (Invitrogen, 31765)
+50 ml FBS Gold (PAA, A15-151)
Harvesting agent
Accutase [PAA (L11-007)]
RECORDING BUFFERS
Extracellular recording buffer (EC), in mM: 145 NaCl, 4 KCl,
1MgCl2, 2 CaCl2, 10 HEPES, 10 Glucose; adjust pH to 7.4 with
NaOH.
Intracellular recording buffer (IC), in mM: 120 KCl, 10 HEPES,
5 CaCl2, 1.7 MgCl2, 4 K2ATP, 10 EGTA; adjust pH to 7.2 with
KOH, osmolarity to 292 mOsm with Saccharose.
METHODS
CELL CULTURE PROTOCOLS
Culturing of cells from frozen vials
(1) Prepare 35 ml cell culture thawing medium.
(2) Thaw the vial quickly in a 37◦C water bath and add to thawing
medium.
(3) Transfer the thawing medium with the cells to a T175 ﬂask
containing pre-heated culture medium.
(4) After 3–4 h, exchange thawing medium with cell culture
medium.
(5) Sub-culture after 2 days.
Sub-culturing
(1) Remove culture medium.
(2) Wash with 10 ml PBS.
(3) Remove PBS and add 2 ml Accutase.
(4) Incubate at room temperature (∼4 min).
(5) Make sure that the cells have a round shape before tapping.
(6) Gently tap on the side of the ﬂask and add 5–7 ml culture
mediumand resuspend the cells byworking the cell suspension
up and down 5–10 times.
(7) Determine the cell density and viability by counting the cells
in a Hemocytometer using Trypan Blue.
(8) Add the number of cells to themother ﬂask and the experiment
ﬂasks according to the subculturing plan below.
(9) Grow the cells at 37◦C, 5% CO2 until roughly 80% of the avail-
able surface is coveredwith cells, corresponding to a conﬂuency
of the cells of 80%.
Sub-culturing plan for making mother ﬂasks and experiment ﬂasks
(1) Add1.85×106 cells perT175ﬂask for sub-culturing/experiments
after 48 h.
(2) Add0.8×106 cells perT175ﬂask for sub-culturing/experiments
after 72 h.
(3) Add0.3×106 cells perT175ﬂask for sub-culturing/experiments
after 96 h.
Cell harvesting for automated electrophysiology patch clamp
experiments (for T175 ﬂask)
The cell harvesting for the automated patch clamp experiment
should be carried out right before the start of the experiment.
Typically, good results can be obtained until up to 4 h after
preparation.
The aim of the cell harvesting procedure is to bring the adher-
ently growing cells into suspension while fully maintaining their
viability and physiological properties. After preparation, the cell
suspension should consist of isolated, single cells. The abundant
presence of cell clusters as well as fragments from dead cells would
inevitably lead to unsatisfying success rates.
(1) Remove culture medium and wash with 7 ml PBS.
(2) Add 2 ml Accutase per T175 culture ﬂask.
(3) Incubate the culture ﬂask at room temperature for ∼4 min
(ensure that the cells have reached a round shape and begin to
detach before proceeding to the next step; see note 2).
(4) Gently tap on the side of the culture ﬂask a few times. This
should at this time be sufﬁcient to detach almost all of the cells
from the ﬂask bottom.
(5) Add 8 ml serum free medium and resuspend the cells by slowly
working the cell suspension up and down 5–10 times. This step
is crucial to allow aprecise counting in the next step. Resuspend
just as vigorous as needed to obtain single cells and to avoid cell
clusters. Don’t do more than needed since this might damage
some of the cells. Avoid air bubbles.
(6) Determine the cell density and viability by diluting an aliquot
1:2 in Trypan Blue and count the cells in a Hemocytometer.
Also determine the number of cell clusters vs. number of single
cells.
(7) Adjust cell density to 3 million cells per ml. You should gain at
least 12 ml of cell suspension which are then placed in the cell
container of the QPatch (“QStirrer”).
PREPARATION OF TEST COMPOUND SAMPLE DILUTIONS
For testing with the automated patch clamp systems, dilutions of
the test samples in the ﬁnal test concentration have to be prepared
and placed in a 96-well plate. This so called “compound plate”
should be prepared immediately before the experiment. The plate
canbe either a plastic disposable or a reusable tray, accommodating
glass inserts. The latter is recommended, since certain types of test
compounds tend to adhere to the walls of plastic ware, which may
reduce the concentration actually being tested (see also note 7).
AUTOMATED ELECTROPHYSIOLOGICAL RECORDINGS
After loading the compound plates and the harvested cells into
the instrument, a previously deﬁned assay protocol is started to
carry out the measurements. The assay protocol contains cell type
speciﬁc settings for establishing the patch clamp recording con-
ﬁguration, as well as “voltage protocols” to elicit the ion channel
currents and “application protocols” that determine the order and
timing of drug applications.
While the settings to achieve the recording conﬁguration for
most common hERG expressing cell lines are typically provided
by the instrument supplier, and are therefore not discussed here,
we will provide detailed information about setting up the voltage
and application protocols in the following sections.
Voltage stimulation protocol for hERG
As a voltage gated channel, the hERG channel can be opened and
closed by varying the membrane potential. This is accomplished
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by applying appropriate voltage stimulation protocols, which has
to be set up in the appropriate software section of the instrument.
Typical for voltage gated potassium channels, the hERG chan-
nels opens and partially inactivates at positive voltages. However,
in contrast to most other potassium voltage gated channels, the
hERG channel shows a very prominent tail current at repolariza-
tion which can be even larger than the current recorded during
depolarization. The protocol shown in Figure 1A shows a widely
used stimulation protocol.
From a holding potential of −80 mV, the cell is brieﬂy clamped
at −50 mV to test leak current at this potential with closed
hERG channels (“baseline step”). This is followed by a depo-
larization to +40 mV, where the hERG channels are alternating
between the open and the inactivated state. After returning
to −50 mV, the inactivated subpopulation of hERG channels
rapidly recovers from inactivation and switches into the open
state, from where the channels slowly close. This results in
a large tail current to be observed in the second −50 mV
phase.
A cell expressing hERG channels will respond to this stimu-
lation protocol with a typical current signature, which can be
unequivocally identiﬁed as a hERG current, as shown inFigure 1B.
To quantify the hERG current amplitude, values for “baseline”
and “peak tail current” are determined by averaging the recorded
currents during the baseline step and at the beginning of the
second – 50 mV period [these time intervals are marked by the
red dotted lines (“cursors”) in Figure 1B]. The hERG channels
are in different states during the two −50 mV phases. In the
phase preceding the baseline measurement, the cell is clamped
at holding potential and the hERG channels are fully closed. The
potential of −50 mV is not sufﬁcient to open closed hERG chan-
nels, so the entire channel population of the cell remains closed.
Any current recorded during this period is therefore considered
not originating from hERG channels (“baseline current” or “leak
current”). In contrast, after the depolarization to +40 mV, some
of the hERG channels are in an open state, but most of them
are in a non-conducting, inactivated state. After repolarizing
back to −50 mV, recovery from inactivation is a very fast pro-
cess. Therefore, the hERG current reaches its highest peak at the
beginning of the repolarization to −50 mV (“peak tail current”).
The “baseline” level measured before, representing the isolated
leak current, will be subtracted from the peak tail current for
correction.
Application protocols
For evaluation of drug effects, after establishment of the record-
ing conﬁguration the voltage stimulation protocols are performed
in equidistant time intervals of 15 s while different liquid solu-
tions are applied to the cell. For analysis, the current amplitudes
of each recorded stimulation protocol can be plotted vs. time.
FIGURE 1 | (A) Stimulation protocol for hERG channel measurements. (B) Example of hERG recordings showing the effect of Cisapride. Four representative
traces from the same cell are superimposed to visualize the effect of increasing concentrations of the known hERG blocker Cisapride.
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FIGURE 2 | Current vs. time (I/t) plot of a three point dose-response
assessment of Cisapride on hERG currents. Downward arrows at the top of
the ﬁgure mark time points where saline or test compound is applied, and
horizontal bars indicate the duration of exposure. The last two data points
before the next application (marked by colored points) are averaged to
calculate the effect of the preceding drug application. Drug applications are
performed twice to ensure saturation of drug effect, where only the second
drug application is used for data analysis.
Figure 2 shows an example of a standard application proto-
col. After a stabilization period, fresh saline is applied to the
cell and a control recording period of at least 3 min should
be recorded. Current amplitude at beginning and end of this
control period should show no signiﬁcant change. The cur-
rent amplitude at the end of the control period is then used
as a reference point for the measured currents after drug appli-
cation. (It is good practice to apply each drug concentration
multiple times, e.g., twice, as shown in Figure 2; see notes
3, 6, and 7.)
Data ﬁltering and dose-response analysis
A typical dose-response curve (DRC) for hERG channel testing
will be calculated from a minimum of three and up to eight dif-
ferent drug concentrations, where each drug concentration will
be tested on at least three different cells. While it is common
practice to test more than one drug concentration on a sin-
gle cell (as shown in Figure 2), the number of concentrations
applied to a cell is limited by the life time of the electrophys-
iological recording, which is often not more than 30–40 min.
After this period, relevant quality criteria of the recording (see
notes 4, 5) tend to degrade. On the other hand, each drug appli-
cation should be given enough time to allow the drug effect to
reach steady state (see note 6). Therefore, the number of test
concentrations that are applied to a cell is limited. The combi-
nation of the number of drug concentrations to be tested and a
sufﬁciently long drug exposure time must not exceed the aver-
age life time for a stable, high quality recording in whole cell
conﬁguration.
The test concentrations can be distributed over several cells and
the data recombined during analysis. The built in data analysis of
theQPatch software is capable to automatically group all data from
cells that where treated with the same compound and to calculate
the DRCs accordingly (see Figure 3). However, a thorough quality
control which ﬁlters out all low quality recordings should precede
this step.
A recording from a cell that qualiﬁes for inclusion into further
data analysis, e.g., for DRC ﬁtting (Figure 3) should meet at least
the following criteria (see also note 9):
(1) The membrane resistance (Rm) should not fall below a given
threshold (e.g., 500 M) at any time (see note 4)
(2) The series resistance (Rs) should not exceed a given threshold
(e.g., 10 M) at any time (see note 5)
(3) The initial I_hERGpeak tail current should not be smaller than
a given value (e.g., 250 pA)
(4) The leak current should not be greater than 20% of the inital
hERG current at any time
(5) The change in current during the control phase (“run down”
or “run up”), should not exceed a given value (e.g., ±10%), see
note 8.
To demonstrate the effect of quality control using the key
parameters Rm and Rs, we analyzed the percentage of remaining
hERG current after treatment with 100 nM Terfenadine in a test
data set of 22 recordings (see Table 1). Quality control parameters
for Rm and Rs where deﬁned and used to divide the test set into an
“accepted” and a “rejected” subgroup, and the mean and standard
deviation (SD) of relative remaining currents for each subgroup
was calculated. Table 1 shows the effects of applying quality criteria
for Rm, Rs, or both. The subsets with good Rm and Rs values show
reduced SD and more reliable data. Therefore, especially during
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FIGURE 3 | Dose-response fit through the data of nine cells (each
identified by a unique color) with two concentrations of Terfenadine
applied to each cell. For each cell, hERG tail current values
representative for each compound concentration where determined as
shown in Figure 3, and normalized to the unblocked hERG current
value which was recorded at the end of the saline period before the
ﬁrst compound application. The combined data of all nine cells was
then ﬁtted to the hill equation y = ch/(IC50h+ch) to estimate the half
maximal inhibition concentration (IC50 value) and hill coefﬁcient h for
this compound (IC50 = 72 nM, h = 0.8).
Table 1 | Influence of quality control on the relative remaining hERG
current after block with 100 nMTerfenadine.
Quality criterium Relative remaining current after
application of 100 nMTerfenadine
Accepted Rejected
Rm > 150 M 60 ± 13% (n = 18) 80 ± 78% (n = 4)
Rs < 15 M 61 ± 15% (n = 16) 70 ± 60% (n = 6)
Rm > 150 M and Rs < 15 M 57 ± 11% (n = 14) 74 ± 52% (n = 8)
A test set of 22 cells was treated with 100 nMTerfenadine and the relative remain-
ing hERG current was measured. Different quality criteria were applied to divide
the test set into two subgroups, named “accepted” and “rejected.” For each
criterium, the results of the subgroups are given as mean ± SD (number of cells).
routine screens with small sample sizes, excluding data with poor
Rs or Rm is highly recommended.
On the QPatch and Patchliner assay softwares, these quality cri-
teria can be conveniently checked by setting up a customized plot
which shows I_hERG, Rm, Rs on a combined panel. Alternatively,
these can be set up as automated quality controls, based on user
deﬁned so called “data ﬁlters.” Such data ﬁlters enable the user to
deal with voluminous amounts of data typical for large projects.
Of course, rejecting a large number of cells comes at
a signiﬁcant cost. In large screens, a statistical analy-
sis of test datasets may help to ﬁnd the exact thresholds
for quality criteria in order to balance data quality against
economics.
NOTES
NOTE 1: CELL LINE
A number of excellent validated hERG channel expressing cell
lines are commercially available (e.g., from ChanTest, Cleveland,
OH, USA; Millipore Merck KGaA, Darmstadt, Germany; CCS
Cell Culture Service, Hamburg, Germany; bSys, Basel, Switzer-
land; Anaxon, Berne, Switzerland), or can be constructed using
well-established molecular biology techniques. Also, cell lines
conveniently provided as frozen cells (Donovan et al., 2011) are
available (e.g., from Cytocentrics, Rostock, Germany and CCS
Cell Culture Service, Hamburg, Germany). Especially with the
possibility to patch cells directly from frozen stocks, these greatly
ease the requirements for cell culture works making cell culture a
much more manageable process. When deciding on a cell line, the
channel expression rate in suspension should be considered, as this
may be signiﬁcantly different from the expression rate in adherent
cells. When channel expression is low after cell harvesting, FCS in
the medium as well as incubating and growing the cells at lower
temperature can help to recover the current. With some cell lines
we have made good experience with incubating the cells at 8◦C for
1–3 h after harvesting before the patch clamp experiment, which
has increased the hERG current amplitudes. Vendors of auto-
mated electrophysiology instruments make recommendations on
cell lines suitable for their instruments, and cell line vendors pro-
vide validation data of their lines used on planar patch clamp
systems.
It has been discussed whether cell lines based on CHO cells
or HEK cells provide more relevant data (Wis´niowska and Polak,
2009). Independent of which cell type is used, however, it is vital
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to validate the channel response well, including data of reference
compounds, and to make sure that no non-hERG background
currents confound the data.
NOTE 2: CELL DETACHMENT
Quality of the cells will critically depend on incubation time in the
cell detachment agent before harvesting. When the incubation is
too short, cells will not detach from the ﬂask easily and detachment
will require a great extent of mechanical interaction, like knocking
on the side of the ﬂask. As a result, cells will be damaged when
they detach from the ﬂask, resulting in poor success rates in the
patch clamp experiments. The amount of cell damage can also
easily assessed by a viability staining of the cell preparation with
trypan blue and should be <5%. When cells are incubated for too
long, the seal rate in experiments is often observed to be excellent;
however, seal stability often becomes poor.
NOTE 3: USE OF DOUBLE DRUG APPLICATIONS
In the example given in Figure 2, each drug concentration is
applied twice (“double drug application”). From the example
given, it is easy to see that extrapolation of the time course of
compound effect following the ﬁrst drug application (dashed lines
and asterisk) shows a signiﬁcant difference to the actual time
course after the second drug application of the same concentra-
tion, demonstrating that double drug applications can give more
accurate results compared to single drug applications. This is par-
ticularly important for hydrophobic (“sticky”) compounds, where
even more (sometimes more than four) compound applications
may be required before steady state of compound effect is reached,
see note 7 and Figures 2 and 6.
NOTE 4: PROBLEMS INTRODUCED BY INSUFFICIENT MEMBRANE
RESISTANCE
The total membrane resistance (Rm) of an intact, healthy cell with
closed ion channels is in the order of several G. When the cell
is placed on a patch clamp chip and recording conﬁguration is
established, a fraction of the cells membrane is sucked into a small
hole in the surface of the chip. While the cell membrane in contact
with the rim of the hole ideally forms an electrically tight seal with
the material of the chip, the membrane in the center of the hole
ﬁnally becomes ruptured, which allows contact of the ampliﬁer to
the interior of the cell through the hole. In this recording conﬁg-
uration (the so called “whole cell” conﬁguration), a high value of
the measured membrane resistance indicates that the rest of the
cell membrane as well as the cells contact to the chip are intact.
This is the prerequisite of high quality recordings. Under condi-
tions where the hERG channels are closed, for example at holding
potential or during the baseline step, almost no “leak” currents
should be visible in the recording, indicating a high Rm.
In Figure 4, two example recordings from the same cell, with
different Rm, are compared. The blue trace is recorded shortly
after obtaining the whole cell conﬁguration. It represents a cell
with a good membrane resistance in the G range. At holding
potential (begin and end of the trace) and during the baseline step
the recorded“leak”current is close to zero. In contrast, the red trace
shows a hERG recording from the same cell after Rm had dropped
to ∼100 M. The uncorrected peak tail current has dropped from
1600 to 1300 pA.At holding potential and during the baseline step,
the “leak” currents deviate signiﬁcantly from zero. The peak tail
current can be correctedwith the baseline level (as recommended),
the corrected peak tail current will be less affected. However, with
increasing degradation of Rm the results will ﬁnally become highly
inaccurate.
NOTE 5: PROBLEMS INTRODUCED BY LARGE SERIES RESISTANCE
The series resistance (Rs), also commonly referred to as access
resistance, is the electrical resistance between the ampliﬁer input
and the cell membrane of the recorded cell. In automated patch
clamp, it is largely determined by the opening diameter of the hole
in the patch clamp chip that makes contact to the cell. However, Rs
may further be increased when the membrane that spans the hole
is only partially ruptured, or for example when cell organelles
are being drawn into the hole. With Rs being very large, the
ampliﬁer is not able to fully control the electrical potential of
the cell membrane. As a result, the actual cell membrane poten-
tial may deviate signiﬁcantly from the potentials deﬁned by the
voltage stimulation protocol. The ion channels will therefore not
be accurately stimulated, and thus their current responses will be
altered.
Figure 5 shows an example of the typical artifacts introduced
by large Rs when recording hERG currents.
As a rule of thumb, when doing dose-response recordings, Rs
should be as small as possible (preferably < 10 M) and stable
over time.
NOTE 6: INCOMPLETE STEADY STATE OF DRUG EFFECTS
The time needed for a compound effect to reach steady state varies
from compound to compound.
Failure to achieve steady state before applying the next com-
pound concentration will lead to underestimation of the drug
effect and therefore to artiﬁcially right-shifted DRCs.
Whether a sufﬁcient steady state has been reached can be judged
by examining the I/t plot of the recording.
Terfenadine is an example of a compound for which the
results of IC50 measurements critically depend on experimen-
tal conditions. For manual patch clamp measurements, 23-
fold differences have been found in literature values (Kirsch
et al., 2004). Due to its hydrophobic or “sticky” nature, the
compound is particularly difﬁcult to measure accurately with
automated patch clamp devices (see note 7). Among several
known hERG inhibitors tested (Guo and Guthrie, 2005), Terfe-
nadine exhibited one of the largest discrepancies (10 vs. 77 nM)
in hERG IC50 values when comparing standard patch clamp
data to automated data. The compound also reaches steady
state of drug block very slowly, so that prolonged drug expo-
sure times have to be considered for accurate dose-response
assessments.
In the“bad practice”example shown in Figure 6A, the blocking
effect of Terfenadine is evaluated with the same protocol as in
Figure 2. With the ﬁrst applied drug concentration of 30 nM,
almost no block is reported by the assay. Analysis of the I/t plot
clearly reveals that the drug effect develops very slowly, so that
steady state is not reached before the next drug concentration is
applied. Increasing the drug application time increases current
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FIGURE 4 | Effect of small membrane resistance (Rm).Two superimposed
hERG recordings from a cell with instable membrane resistance are shown.
The blue trace represents an early recording from this cell, where Rm has a
high value in the G range. The red trace was recorded from the same cell
after Rm dropped to ∼100 M. The baseline (or “leak”) currents recorded
during the brief −50 mV “baseline step” are indicated by horizontal dotted
lines. The inset in the upper right corner provides a zoomed view on how the
baseline current is determined during the baseline step. Due to the drop in
Rm, baseline current and peak tail current are shifted to a comparable extent.
The difference between baseline and peak tail current, indicated by the
double headed vertical arrows, is more robust to changes in Rm than
uncorrected peak tail current alone.
FIGURE 5 | Effect of series resistance increase on hERG measurements. In this drastic example, a change in series resistance (Rs), combined with a stable,
but critically low membrane resistance (Rm = 120 M), leads to a signiﬁcant distortion in the readout.
blockade, and repeated drug applications improve the actual drug
concentration at the target. A “good practice” example is shown in
Figure 6B, where the number of repeated drug applications and
the drug exposure time is doubled, an acceptable steady state is
reached, and a signiﬁcant drug induced block of 30% is found for
the same concentration.
Therefore, the assay scheme in the ﬁrst example leads to an
underestimation of the compound effect. A prolongation of the
time periods between the drug applications leads to more accurate
IC50 determinations for such slowly acting compounds.
To demonstrate the effect of incomplete steady state, we
analyzed the effect of a prolonged drug exposure to Terfenadine.
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FIGURE 6 | Good and bad practice examples for steady state of drug
induced block byTerfenadine. (A) Bad practice example of an I/t plot
showing insufﬁcient steady state of block, which would lead to
underestimation of the drug effect. (B) Good practice example where the
drug exposure time as well as the number of drug application repeats has
been doubled, leading to an acceptable steady state.
The recording shown in Figure 6A is representative for a test
data set of seven recordings featuring a drug exposure time of
150 s per compound. The average IC50 for Terfenadine in this
data set is 180 nM (n = 7). In contrast, when we doubled the
drug exposure time, as shown in Figure 6B, we obtained an
average IC50 of 72 nM under otherwise similar conditions (see
Figure 3).
NOTE 7: RECOMMENDATIONS FOR STICKY COMPOUNDS
Some compound classes are difﬁcult to dissolve in aqueous
solutions and also known for their notorious “sticky” behavior,
typically a result of their hydrophobic nature. It has been com-
monly observed that with these compounds, the actual applied
concentration is in fact reduced by adherence of compound
molecules to the walls of the containers where the compound
dilutions are stored in. The result of such effects would be an
artiﬁcially right-shifted DRC, and therefore may lead to failure of
detection of problematic hERG effects.
To reduce such unwanted effects, the following precautions are
recommended:
• Use glassware as a standard for compound plates, vials, and
even pipette tips.
• Set up the dilutions in rather large vials (at least 1 ml).
• Prepare a DMSO stock solution at a 1000 fold higher concen-
tration than the maximum tested concentration.
• To prepare the various test concentrations, dilute the stock solu-
tion ﬁrst with DMSO, then dilute 1:1000 with EC, thus keeping
the ﬁnal DMSO concentration at a constant level of 0.1%. An
increased DMSO concentration of up to 1% may be tolerated
in your assay.
• If feasible prepare compound dilutions manually and closely
look for precipitation.
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• Prepare the compound plate immediately before running the
experiment.
It may be required to analyze solubility and ﬁnal concentra-
tions of compounds in buffer solutions using, e.g., LC/MS (when
available).
NOTE 8: RUN DOWN
From time to time, a downward trend of the hERG cur-
rent amplitudes during the control phase, i.e., independent of
any drug application, may be observed. This phenomenon is
commonly referred to as “run down”. Including cells exhibit-
ing run down into dose-response analysis should be strictly
avoided. Otherwise, it will result in artiﬁcially left-shifted DRCs,
and therefore may lead to false positive identiﬁcation of hERG
blockade.
The main focus to ﬁx run down problems should be the cell
culture. Cell density in the culture ﬂasks should not exceed 80%
conﬂuency, and CO2 concentration be kept sufﬁciently constant.
Using an incubator that is frequently opened (i.e., because it
accommodates cell cultures from different projects) may lead to
CO2 ﬂuctuations that might negatively affect cell quality.
It is also a good advice to check pH and osmolarity of IC and
EC recording buffers before use, especially if frozen stocks are
employed.
NOTE 9: HILL COEFFICIENT
From dose-response (or IC50)-ﬁts with a sufﬁcient number of
concentrations, the Hill coefﬁcient can also be calculated with
standard assay software packages. For many channel-compound
interactions, the Hill coefﬁcient would be expected to be close to
1. While other Hill coefﬁcients are possible, these should be crit-
ically reviewed. Typical problems in experiments that can lead to
Hill coefﬁcients incorrectly deviating from one, and, consequently
would produce incorrect IC50 values, are:
A Hill coefﬁcient greater than one (steep IC50 curve) is often
caused by underestimation of compound effects in particular at
small concentrations, e.g., due to no steady state in compound
effects (seenote 6), absorptionof compound to, e.g., tubematerials
(see note 7), and other reasons.
A Hill coefﬁcient smaller than one often stems from underes-
timation of compound effects at high concentrations (e.g., due
to poor voltage clamp conditions at large currents or large series
resistance, see note 5), or overestimation of compound effects at
low concentrations, e.g., due to run down effects (see note 8), that
might be falsely interpreted as slow compound effects.
OUTLOOK
This article focuses on protocols to identify cardiac safety issues
caused by hERG ion channel blockade early in drug discov-
ery programs by high quality medium throughput automated
electrophysiology screening using cells expressing the hERG ion
channel. The physiological signiﬁcance of these recordings can
be improved, at reduced throughput, by performing record-
ings at or near physiological temperature (Polonchuk, 2012).
In addition to screening on the particularly important hERG
ion channel, assessing the effects of compounds on other car-
diac ion channels may be required. Recently, automated patch
clamp screening of compound effects on the action potential in
stem cell derived cardiomyocytes has become possible (Stoelzle
et al., 2011a; Milligan and Möller, 2013). These assays provide
information to further assess the cardiac safety of compounds.
However, currently more validation of stem cell based assays is
required before these can be routinely used for cardiac safety
investigations.
Advances in the parallelization of patch clamp electro-
physiology robots will further increase the throughput of
patch clamp screening. A robot allowing parallel measure-
ments of up to 768 wells with gigaseal and corresponding
low leak currents is now available (Syncropatch PE, Nanion
Technologies, Munich), and the throughput of patch clamp
electrophysiology screening can be expected to increase even
further.
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